首页 | 本学科首页   官方微博 | 高级检索  
     

依达拉奉与奥扎格雷钠联用治疗急性脑梗死临床研究
引用本文:周庆海. 依达拉奉与奥扎格雷钠联用治疗急性脑梗死临床研究[J]. 中国卫生产业, 2013, 0(23): 38-39
作者姓名:周庆海
作者单位:山东省武城县人民医院,山东武城253300
摘    要:目的探讨依达拉奉与奥扎格雷钠联用治疗急性脑梗死临床效果及安全性。方法选取我院2010年3月-2012年5月收治急性脑梗死患者160例,采用随机数字表法分为对照组和联合治疗组,每组各80例;其中对照组患者采用奥扎格雷钠静脉滴注治疗;联合治疗组;其中在对照组治疗基础上,加用依达拉奉静脉滴注治疗;比较两组患者临床改善总有效率,治疗前后神经功能缺损(NIHSS)及日常生活能力(BI)评分及不良反应发生情况等。结果对照组和联合治疗组患者临床改善总有效率分别为80.O%,93.8%;联合治疗组患者临床改善总有效率明显高于对照组,组间比较差异显著(P〈0.05);对照组与联合治疗组患者治疗前神经功能缺损评分及BI评分组间比较无显著差异(P〉0.05);两组患者治疗后神经功能缺损评分及BI评分较治疗前明显改善,且联合治疗组患者改善程度明显优于对照组,组问比较差异显著(P〈0.05);同时两组患者并发症发生率组间比较无显著差异(P〉0.05)。结论依达拉奉与奥扎格雷钠联用治疗急性脑梗死临床效果确切,可显著改善神经功能缺损症状,恢复13常生活能力,且未提高并发症发生风险,具有临床使用价值。

关 键 词:依达拉奉  奥扎格雷钠  急性脑梗死  疗效  安全性

Clinical Study of Edaravone Treatment Combined with Sodium Ozagrel on Acute Cerebral Infarction
ZHOU Qinghai. Clinical Study of Edaravone Treatment Combined with Sodium Ozagrel on Acute Cerebral Infarction[J]. China Health Industry, 2013, 0(23): 38-39
Authors:ZHOU Qinghai
Affiliation:ZHOU Qinghai( The people's Hospital of Wu cheng county in Shandong province, Shandong 253300, China)
Abstract:Objective To investigate the therapeutic effect and security of edaravone treatment combined with sodium ozagrel on acute cerebral infarction. Methods 160 patients with acute cerebral infarction were chose in the period from October 2010 to March 2012 in our hospital and randomly divided into two groups including control group (80 patients) with sodium ozagrel infusion treatment and combined treatment group (80 patients) with edaravone treatment on the basis of control group treatment; and the clinical improving efficiency, the NIHSS and BI scores before and after treatment and complication occurrence of both groups were compared. Results The clinical improving efficiency of control group and combined treatment group were separately 80.0%, 93.8%; The clinical improving efficiency of combined treatment group were significantly higher than control group (P〈0.05). There was no significant difference in NIHSS and BI scores before treatment between control group and Combined treatment group (P〉0.05); The NIHSS and BI scores after treatment of both groups were significantly better than before treatment (P〈0.05) ; and the improving degree of combined treatment group were significantly better than control group (P〈0.05). There was no significant difference in complication incidence between control group and Combined treatment group (P〉0.05). Conclusion Edaravone treatment combined with sodium ozagrel on acute cerebral infarction possess perfect effects, can efficiently improve neurological deficit, restore the normal life ability, do not higher the risk of complication, and is worthy of clinical application value.
Keywords:Edaravone  Sodium ozagrel  Acute cerebral infarction  Therapeutic effects  Security
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号